NATH BIO-GENES (I) Latest Share Price (NATHBIOGEN)
TODAY IN ONE LINE
NATHBIOGEN jumped 3.0% on above-average volume (3.3x avg), outperforming Nifty's 0.3% move, with no exchange filing today, suggesting a market-driven move.
With a market cap of ₹285.06 Cr., it trades at a P/E of 8.00. Track live valuations, technical indicators, and peers comparison below. Check delivery conviction and recent filings to build your view.
How good is this company?
Overall performance across 5 key dimensions.
NATH BIO-GENES (I) flags & news
Key strengths, potential risks, and recent updates.
Green Flags
- ●Healthy Operating MarginsOPM is structurally strong at 16.5%
- ●Reasonable ValuationTrading at a moderate P/E of 7.6x
- ●Virtually Debt-FreeVery low Debt-to-Equity of 0.18x
- ●Positive Free Cash FlowFCF has been positive for 3 consecutive years
- ●Zero Pledge RiskNo recent active promoter pledging found
Red Flags
- ●Sales ContractionQuarterly sales dropped 1.7% YoY
- ●Poor Capital ReturnsLow ROE of 7.8%
Latest NATH BIO-GENES (I) News
What changed recently?
Recent events, corporate actions, and announcements.
NATH BIO-GENES (I) valuation: P/E, P/B and sector benchmarks.
Twelve years of multiples investors have paid for NATH BIO-GENES (I), framed against the sector median so the premium or discount is obvious at a glance.
NATH BIO-GENES (I) trades at a P/E of 8.00× and P/B of 0.43×.
Market-priced ratios use the latest available quote; accounting metrics use the latest reported filing. Compare values with matched peers and the company's own history.
Valuation
Profitability
Growth
Financial Health
NATH BIO-GENES (I) technical analysis: indicators, pivots and CPR.
Latest RSI, MACD and moving-average signals plus the latest pivot and Central Pivot Range levels for NATH BIO-GENES (I) — derived from the latest tape, not yesterday's close.
NATH BIO-GENES (I) last traded at ₹151.8 with an intraday range of ₹145.02–₹152.9 — latest indicator, pivot and CPR signals below.
Pivot points
Standard pivot — most widely referenced.
Pivot levels · Classic
Last: ₹151.80| Level | Price (₹) | Distance | % Δ |
|---|---|---|---|
| R4 | 170.55 | +18.75 | +12.35% |
| R3 | 162.67 | +10.87 | +7.16% |
| R2 | 157.79 | +5.99 | +3.94% |
| R1 | 154.79 | +2.99 | +1.97% |
| PIVOT | 149.91 | -1.89 | -1.25% |
| CURRENT | 151.80 | — | — |
| S1 | 146.91 | -4.89 | -3.22% |
| S2 | 142.03 | -9.77 | -6.44% |
| S3 | 139.03 | -12.77 | -8.41% |
| S4 | 131.15 | -20.65 | -13.60% |
NATHBIOGEN is trading Above CPR, indicating Bullishness
CPR is Wider, suggesting unlikely for trending moves
Day's range: ₹146.2–₹150
Trading Above opening range, showing Bullishness
NATH BIO-GENES (I) financials: P&L, balance sheet, cash flow, ratios.
Reported annual and quarterly results for NATH BIO-GENES (I) — consolidated or standalone — with margins, YoY growth and key ratios inline.
NATH BIO-GENES (I) reports its full P&L, balance sheet, cash flow and ratios on this page — current market capitalisation of ₹285.06 Cr. and reported EPS of ₹17.18.
| Metric | Mar 2025 | Mar 2026 |
|---|---|---|
| Revenue from Operations | 365 | 445 ▲ 22.0% |
| Sales Growth YoY %Derived | 9.71% | 21.98% |
| Other Income | 5 | 8 ▲ 71.8% |
| Total Income | 369 | 453 ▲ 22.6% |
| 136 | 202 ▲ 48.7% | |
| Gross ProfitDerived | 229 | 244 ▲ 6.2% |
| Gross Margin %Derived | 62.85% | 54.73% |
| 180 | 191 ▲ 6.5% | |
| EBITDA (Operating Profit)Derived | 50 | 52 ▲ 5.3% |
| OPM %Derived | 13.65% | 11.78% |
| 15 | 26 ▲ 74.9% | |
| Profit Before Tax (PBT) | 41 | 46 ▲ 14.1% |
| 2 | 5 ▲ 135.5% | |
| Effective Tax %Derived | 4.89% | 10.09% |
| Total Profit for Period | 39 | 42 ▲ 7.9% |
| Net Profit (Owner's PAT)Derived | 39 | 42 ▲ 7.9% |
| Net Profit Margin %Derived | 10.58% | 9.35% |
| PAT Growth YoY %Derived | -2.57% | 7.85% |
| Earnings Per Share (EPS ₹) | 20.31 | 21.91 ▲ 7.9% |
| Diluted Shares Outstanding (Cr) | 2 | 2 ▲ 0.0% |
| Share of Profit from Associates/JVs | — | — |
| Other Comprehensive Income (Net of Tax) | -0 | -2 ▼ 431.8% |
| Total Expenses (incl. D&A & Interest) | 329 | 407 ▲ 23.6% |
| Material Cost % of RevenueDerived | 61.81% | 68.79% |
| Employee Cost % of RevenueDerived | 8.91% | 8.04% |
| Other Cost % of RevenueDerived | 40.30% | 34.91% |
| Interest Coverage (x)Derived | 4.39x | 3.03x |
| Period | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | Trend |
|---|---|---|---|---|---|
| Revenue from Operations | 301 | 333 ▲ 10.4% | 365 ▲ 9.7% | 445 ▲ 22.0% | |
| Sales Growth YoY %Derived | — | 10.37% | 9.71% | 21.98% | |
| Other Income | 1 | 1 ▲ 13.2% | 5 ▲ 625.5% | 8 ▲ 71.8% | |
| Total Income | 302 | 333 ▲ 10.4% | 369 ▲ 10.9% | 453 ▲ 22.6% | |
135 | 134 ▼ 0.8% | 136 ▲ 1.5% | 202 ▲ 48.7% | ||
| Gross ProfitDerived | 167 | 199 ▲ 19.4% | 229 ▲ 15.2% | 244 ▲ 6.2% | |
| Gross Margin %Derived | 55.33% | 59.84% | 62.85% | 54.73% | |
118 | 149 ▲ 26.4% | 180 ▲ 20.4% | 191 ▲ 6.5% | ||
| EBITDA (Operating Profit)Derived | 49 | 50 ▲ 2.3% | 50 ▼ 0.1% | 52 ▲ 5.3% | |
| OPM %Derived | 16.17% | 14.99% | 13.65% | 11.78% | |
13 | 16 ▲ 20.5% | 15 ▼ 6.2% | 26 ▲ 74.9% | ||
| Profit Before Tax (PBT) | 36 | 42 ▲ 14.9% | 41 ▼ 2.4% | 46 ▲ 14.1% | |
1 | 2 ▲ 68.8% | 2 ▲ 2.0% | 5 ▲ 135.5% | ||
| Effective Tax %Derived | 3.19% | 4.68% | 4.89% | 10.09% | |
| Total Profit for Period | 35 | 40 ▲ 13.1% | 39 ▼ 2.6% | 42 ▲ 7.9% | |
| Net Profit (Owner's PAT)Derived | 35 | 40 ▲ 13.1% | 39 ▼ 2.6% | 42 ▲ 7.9% | |
| Net Profit Margin %Derived | 11.62% | 11.91% | 10.58% | 9.35% | |
| PAT Growth YoY %Derived | — | 13.11% | -2.57% | 7.85% | |
| Earnings Per Share (EPS ₹) | 18.43 | 20.85 ▲ 13.1% | 20.31 ▼ 2.6% | 21.91 ▲ 7.9% | |
| Diluted Shares Outstanding (Cr) | 2 | 2 ▲ 0.0% | 2 ▲ 0.0% | 2 ▲ 0.0% | |
| Share of Profit from Associates/JVs | 0 | — ▼ 100.0% | — | — | |
| Other Comprehensive Income (Net of Tax) | 0 | 1 ▲ 4403.4% | -0 ▼ 135.6% | -2 ▼ 431.8% | |
| Total Expenses (incl. D&A & Interest) | 266 | 292 ▲ 9.8% | 329 ▲ 12.7% | 407 ▲ 23.6% | |
| Material Cost % of RevenueDerived | 38.93% | 42.83% | 61.81% | 68.79% | |
| Employee Cost % of RevenueDerived | 7.74% | 8.49% | 8.91% | 8.04% | |
| Other Cost % of RevenueDerived | 31.42% | 36.36% | 40.30% | 34.91% | |
| Interest Coverage (x)Derived | 4.52x | 5.12x | 4.39x | 3.03x |
NATH BIO-GENES (I) segment analysis : revenue and profit mix.
Disclosed business segments at NATH BIO-GENES (I) with their share of revenue and profit, switchable between consolidated and standalone reporting.
NATH BIO-GENES (I) discloses revenue and profit across multiple business segments — toggle between consolidated and standalone views to see the mix.
Segment-wise Financial Analysis
The Bull, Bear, and Flip case for NATH BIO-GENES (I).
Our AI distills the core fundamental drivers supporting NATH BIO-GENES (I), the risks that threaten it, and the quantitative conditions that could weaken the thesis.
NATH BIO-GENES (I)'s investment case rests on 0 positive markers and 1 flagged concerns drawn from the latest reported filings.
What you're getting.
No strengths or opportunities on record.
Key Risks.
SWOT generation temporarily unavailable due to model error. The security token included in the request is invalid.
Flip Conditions.
Valuation risk. a P/E above 10 would leave less room for earnings disappointment.
Reassess if quarterly profit growth turns negative for two consecutive quarters. The bull case relies on compounding earnings.
Watch interest coverage if debt-to-equity climbs above 1.00. Balance sheet risk re-prices growth multiples fast.
Return-quality risk. ROE below 8% would indicate weaker capital compounding.
NATH BIO-GENES (I) peer comparison — same-sector benchmarks.
Same-sector listed peers ranked on P/E, market cap, dividend yield and growth — NATH BIO-GENES (I) is highlighted for quick read-across.
Quick Compare
Peer Comparison
| Company Name |
|---|
NATH BIO-GENES (I) chart patterns: breakouts, tops and bottoms.
Auto-detected classical chart patterns for NATH BIO-GENES (I) — Double Top/Bottom, Head & Shoulders, Triple Bottom and more — with break levels, targets and quality scores across Intraday, Daily and Weekly timeframes.
NATH BIO-GENES (I) delivery volume — last 20 sessions of conviction.
Daily traded volume and delivery percentage for NATH BIO-GENES (I) over 20 sessions — the gap between intraday flipping and genuine accumulation.
Latest session delivery in NATH BIO-GENES (I) stood at 96.5% of traded volume, against a 20-day average of 80.0%.
NATH BIO-GENES (I) announcements: results, concalls, ratings, M&A.
Filings NATH BIO-GENES (I) sent to the exchanges, sequenced as they hit the tape — concall transcripts, results, credit ratings and presentations.
NATH BIO-GENES (I) files concall transcripts, results, credit ratings and corporate-action notices on the NSE and BSE exchange portals — latest 37 documents below.
Clarification - Financial Results
The Exchange has sought clarification from Nath Bio-Genes (India) Limited for the quarter ended 30-Jun-2026 with respect to Regulation 33 of the SEBI…
Record Date
Nath Bio-Genes (India) Limited has informed the Exchange that Record date for the purpose of Dividend & Meeting is 11-Sep-2026.
Shareholders meeting
Nath Bio-Genes (India) Limited has informed the Exchange regarding Notice of Annual General Meeting to be held on September 24, 2026
Initiation of Forensic Audit
Nath Bio-Genes (India) Limited has informed the Exchange about Initiation of Forensic Audit
General Updates
Nath Bio-Genes (India) Limited has informed the Exchange about General Updates
Investor decks & rating reports.
NATH BIO-GENES (I) dividend history, splits and bonus issues.
Every dividend, stock split and bonus issue NATH BIO-GENES (I) has declared, sequenced by announce and record date.
NATH BIO-GENES (I) corporate-action history below covers all declared dividends, stock splits and bonus issues recorded with NSE and BSE.
About NATH BIO-GENES (I): business, sector, key facts.
What NATH BIO-GENES (I) does, where it operates, the people running it, and the numbers that describe the entity behind the ticker.
NATH BIO-GENES (I) operates in the Other Agricultural Products industry under the Fast Moving Consumer Goods sector, listed as NSE: NATHBIOGEN, BSE: 537291.
Nath Bio-Genes (India) Limited is a prominent player in the Indian agricultural sector, specializing in the production, processing, and marketing of hybrid and genetically modified (GM) seeds. Their business model encompasses both domestic and international markets, contributing to a diverse and expansive reach within the industry. The company's activities are primarily focused on providing a comprehensive range of seeds tailored to various agricultural needs.
The company's operations are structured around two core segments: Agricultural Activities and Trading Activities. The Agricultural Activities segment focuses on the cultivation and processing of a wide spectrum of seeds. This includes fiber and oil seeds such as cotton and mustard, which are crucial components of the textile and edible oil industries, respectively. In addition, they offer seeds for various field crops, encompassing cereals like bajra, corn, paddy, wheat, and jowar, contributing to food security and agricultural output. Their portfolio extends to fruit seeds and a comprehensive selection of vegetable seeds, covering a wide variety of popular crops.
Beyond seeds, Nath Bio-Genes also offers a line of crop protection supplements under the brand names WINPro GOLii, WINall, and Win Chi Win. These supplements are designed to enhance crop health, yield, and resilience, addressing critical aspects of modern agriculture. Furthermore, the company supplies forage seeds under the NUTRIMAX GOLD and NUTRIMAX brands, catering to livestock farming and related industries. This diversification into related agricultural products enhances their market positioning and strengthens their customer relationships.
The Trading Activities segment complements their agricultural production, encompassing the buying and selling of agricultural commodities and related products. This vertical integrates with their seed production and crop protection supplement businesses, facilitating efficient market access and supply chain management. The integration between the agricultural and trading activities allows for a more holistic approach to serving the agricultural market, from seed production to post-harvest management and distribution.
Established in 1979 and headquartered in Mumbai, India, Nath Bio-Genes (India) Limited has cultivated a significant presence in the agricultural landscape. Their extensive product portfolio, coupled with their focus on both domestic and international markets, positions them as a key contributor to India's agricultural sector and a significant player in the global seed market.
Related
Peers, sector trends, screeners and strategy playbooks contextual to this stock.
- AGRI-TECH (INDIA) (AGRITECH) Share PricePeer
- AVT NATURAL PRODUCTS (AVTNPL) Share PricePeer
- CHAMAN LAL SETIA EXP (CLSEL) Share PricePeer
- GUJARAT AMBUJA EXPORTS LT (GAEL) Share PricePeer
- GRM OVERSEAS (GRMOVER) Share PricePeer
- Top Gainers TodayScreener
- EMA Crossover ScreenerScreener
- Stock Quality ScorecardScreener
- Technical DashboardScreener
- Results CalendarScreener
- FII Buying ActivityScreener
- All Technical ScreenersScreener
- All Trading StrategiesStrategy
Questions investors ask about NATH BIO-GENES (I) (NATHBIOGEN).
Quick answers grounded in this page's data — price action, fundamentals, ratios and ownership.
01What is the current share price of NATH BIO-GENES (I) (NATHBIOGEN)?
The current share price of NATH BIO-GENES (I) (NATHBIOGEN) is ₹151.80. Today, the stock has gained by ₹4.46 (3.03%), trading in a range of ₹145.02 to ₹152.90. The stock opened at ₹149.00 with a trading volume of 1,09,938 shares.
02Is NATH BIO-GENES (I) stock a good investment for long-term?
NATH BIO-GENES (I) can be considered for long-term investment based on several factors. The company has a market capitalization of ₹285.06 Cr., P/E ratio of 8, ROE of 7.75%, and ROCE of 5.81%. The dividend yield stands at 0%. However, investment decisions should be based on your financial goals, risk appetite, and thorough research. It's recommended to consult with a SEBI-registered financial advisor before making investment decisions.
03What is the 52-week high and low price of NATH BIO-GENES (I) stock?
The 52-week high price of NATH BIO-GENES (I) (NATHBIOGEN) is ₹204.00, while the 52-week low is ₹126.15. Currently trading at ₹151.80, the stock is 20.33% above its 52-week low and 25.59% below its 52-week high. These levels help investors understand the stock's price volatility and trading range over the past year.
04Should I buy NATH BIO-GENES (I) stock at the current price?
Whether to buy NATH BIO-GENES (I) stock at ₹151.80 depends on multiple factors. The stock is currently trading with a P/E ratio of 8 and P/B ratio of 0.43. Today's performance shows a gain of 3.03%. Consider analyzing the company's fundamentals, technical indicators, industry trends, and your investment horizon. Compare these metrics with industry peers and consult a financial advisor for personalized advice.
05What is the dividend yield of NATH BIO-GENES (I) and when is the next dividend?
NATH BIO-GENES (I) offers a dividend yield of 0%, which means for every ₹100 invested at the current price of ₹151.80, you can expect to receive approximately ₹0.00 annually as dividends. The face value of the stock is ₹10.00. For information about the next dividend announcement and ex-dividend date, please check the company's official announcements or visit the BSE/NSE websites.
06What are the key financial ratios and metrics of NATH BIO-GENES (I)?
NATH BIO-GENES (I)'s key financial metrics include: P/E Ratio: 8, P/B Ratio: 0.43, ROE: 7.75%, ROCE: 5.81%, Dividend Yield: 0%, EPS: ₹17.18, Book Value: ₹358.06, and Debt-to-Equity: 0.18. The company's market cap stands at ₹285.06 Cr.. These metrics help evaluate the company's valuation, profitability, and financial health.
07How is NATH BIO-GENES (I) stock performing today in the market?
NATH BIO-GENES (I) stock opened at ₹149.00 and is currently trading at ₹151.80, showing a gain of ₹4.46 (3.03%). The intraday high is ₹152.90 and low is ₹145.02. The trading volume stands at 1,09,938 shares, indicating moderate market participation today.
08What is the P/E ratio of NATH BIO-GENES (I) and what does it indicate?
NATH BIO-GENES (I) has a Price-to-Earnings (P/E) ratio of 8, which means investors are willing to pay 8.00 for every ₹1 of earnings. With an EPS of ₹17.18, this P/E ratio suggests the stock may be undervalued or facing growth challenges. Compare this with industry peers and historical P/E ratios for better context.
The data, ratios and commentary about NATH BIO-GENES (I) (NATHBIOGEN) on this page are published for educational and informational purposes only and are not investment, legal or tax advice. StockeZee is not a SEBI-registered investment adviser, research analyst or portfolio manager, and no content here should be construed as a recommendation to buy, hold or sell any security. Live and historical market data may be delayed, revised by the exchanges, or contain errors; figures sourced from third-party feeds and corporate disclosures may not always be current. Past performance is not indicative of future results, and equity investments carry the risk of capital loss. Before acting on anything you read here, please consult a SEBI-registered financial advisor and read all scheme-related documents carefully.